Emmanuel Iroboudu Okpetu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emmanuel Iroboudu Okpetu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Dike Bevis Ojji
University of Abuja, Abuja, Nigeria
3 shared publications - Gabriel Lamkur Shedul
Cardiovascular Research Unit, University of Abuja, Abuja, Nigeria
3 shared publications - Abigail S. Baldridge
Northwestern University Feinberg School of Medicine
2 shared publications - Lisa Ruth Hirschhorn
Feinberg School of Medicine, Northwestern University, Chicago, USA
2 shared publications - Mark D. Huffman
The George Institute for Global Health, University of New South Wales, Sydney, Australia (A.S., G.S., F.H., S.R.G., M.D.H.).
2 shared publications - Nanna R. Ripiye
University of Abuja Teaching Hospital, Abuja, Nigeria
2 shared publications
Latest Publications
- Open Access
- 14 January 2026
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 21 (1) , 18
Cost-Effectiveness and Implementation Strategies for Hypertension Management Using Non-Physician Healthcare Workers in Low- and Middle-Income Countries: A Systematic Review
Background: This review assessed the cost-effectiveness and implementation strategies of hypertension management by non-physician healthcare workers (NPHCWs) in low- and middle-income countries (LMICs). Methods: A systematic search (inception–May 2024) included adults ≥18 years managed by NPHCWs LMICs, following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Economic evaluations were assessed using Drummond’s checklist and ROBINS-I. Results: Seven studies (2002–2022) conducted across eight countries enrolled 96–10,000 participants and included randomized, modeling, observational, and quasi-experimental designs. NPHCWs included pharmacists, community and village health workers, and nurses. Patients’ mean age ranged 58–71 years, with 57–82% female. Outcomes assessed included cost per mmHg reduction ($INT 2.25 systolic, $INT 2.03 diastolic), per controlled patient ($INT 1.48), annual cost ($INT 0.22–232.31), cost per disability-adjusted life year (DALY) averted ($INT 411.39–4709.96), and per quality-adjusted life year (QALY) gained ($INT 1.04–13.30). Incremental cost-effectiveness ratio (ICERs) varied ($INT 0.41–14,373.97). Strategies included NPHCWs training and community engagement/counseling. Conclusion: Hypertension management by NPHCWs appears cost-effective in LMICs, though more studies are needed for generalizability.
- 14 January 2026
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 21 (1) , 18
Open AccessCost-Effectiveness and Implementation Strategies for Hypertension Management Using Non-Physician Healthcare Workers in Low- and Middle-Income Countries: A Systematic Review
Background: This review assessed the cost-effectiveness and implementation strategies of hypertension management by non-physician healthcare workers (NPHCWs) in low- and middle-income countries (LMICs). Methods: A systematic search (inception–May 2024) included adults ≥18 years managed by NPHCWs LMICs, following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Economic evaluations were assessed using Drummond’s checklist and ROBINS-I. Results: Seven studies (2002–2022) conducted across eight countries enrolled 96–10,000 participants and included randomized, modeling, observational, and quasi-experimental designs. NPHCWs included pharmacists, community and village health workers, and nurses. Patients’ mean age ranged 58–71 years, with 57–82% female. Outcomes assessed included cost per mmHg reduction ($INT 2.25 systolic, $INT 2.03 diastolic), per controlled patient ($INT 1.48), annual cost ($INT 0.22–232.31), cost per disability-adjusted life year (DALY) averted ($INT 411.39–4709.96), and per quality-adjusted life year (QALY) gained ($INT 1.04–13.30). Incremental cost-effectiveness ratio (ICERs) varied ($INT 0.41–14,373.97). Strategies included NPHCWs training and community engagement/counseling. Conclusion: Hypertension management by NPHCWs appears cost-effective in LMICs, though more studies are needed for generalizability.
- Open Access
- 9 January 2025
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 20 (1) , 112
Implementation of Single-Pill Combination Medication for Hypertension Treatment by Nonphysician Health Care Workers at Primary Healthcare Facilities in Nigeria: An Explanatory Mixed Methods Study
Single-pill combination (SPC) therapy improves hypertension control; however, its implementation in primary care settings remains limited. In Nigeria, there is insufficient evidence on factors influencing SPC uptake, particularly from the perspective of healthcare workers (HCWs). This study examined the implementation of SPC medications for hypertension treatment by nonphysician HCWs at primary healthcare facilities (PHCs) in Nigeria. An explanatory sequential mixed methods study was conducted, building on a cluster randomized controlled trial embedded within the Hypertension Treatment in Nigeria Program. The trial compared SPC medications with free-equivalent combination therapies across 60 PHCs (January–June 2021). A subsequent qualitative component (September–December 2021) included two focus group discussions from 30 PHCs assigned to the SPC arm of the trial and five key informant interviews. The Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework was used to assess implementation outcomes and identify facilitators and barriers. Integration of quantitative and qualitative findings was guided by the RE-AIM Qualitative Evaluation for Systematic Translation framework (QuEST). All 30 PHCs assigned to dispense SPCs adopted the medications (Reach/Adoption). Effectiveness: Blood pressure control (<140/90 mm Hg) was 54% (95% CI: 0.52, 0.56) in the SPC arm and 48% (95% CI: 0.46, 0.50) in the free-equivalent arm (cluster-adjusted p = 0.29). Monthly SPC use ranged from 21–37% across sites (Implementation), and 49% of patients remained in care at six months (Maintenance). Facilitators included training on SPC protocols, simplicity of dispensing the regimen, and perceived improvements in patient adherence. Challenges included SPC stockouts and concerns regarding nonphysician HCW capacity to manage complex cases. Policymakers identified the potential role of a Drug Revolving Fund (DRF) to support sustained SPC supply. The findings indicate favorable implementation outcomes associated with SPC use by nonphysician HCWs in PHCs. Addressing supply challenges, maintaining training, and providing supportive supervision may be important for sustaining SPC-based hypertension treatment.
- 9 January 2025
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 20 (1) , 112
Open AccessImplementation of Single-Pill Combination Medication for Hypertension Treatment by Nonphysician Health Care Workers at Primary Healthcare Facilities in Nigeria: An Explanatory Mixed Methods Study
Single-pill combination (SPC) therapy improves hypertension control; however, its implementation in primary care settings remains limited. In Nigeria, there is insufficient evidence on factors influencing SPC uptake, particularly from the perspective of healthcare workers (HCWs). This study examined the implementation of SPC medications for hypertension treatment by nonphysician HCWs at primary healthcare facilities (PHCs) in Nigeria. An explanatory sequential mixed methods study was conducted, building on a cluster randomized controlled trial embedded within the Hypertension Treatment in Nigeria Program. The trial compared SPC medications with free-equivalent combination therapies across 60 PHCs (January–June 2021). A subsequent qualitative component (September–December 2021) included two focus group discussions from 30 PHCs assigned to the SPC arm of the trial and five key informant interviews. The Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework was used to assess implementation outcomes and identify facilitators and barriers. Integration of quantitative and qualitative findings was guided by the RE-AIM Qualitative Evaluation for Systematic Translation framework (QuEST). All 30 PHCs assigned to dispense SPCs adopted the medications (Reach/Adoption). Effectiveness: Blood pressure control (<140/90 mm Hg) was 54% (95% CI: 0.52, 0.56) in the SPC arm and 48% (95% CI: 0.46, 0.50) in the free-equivalent arm (cluster-adjusted p = 0.29). Monthly SPC use ranged from 21–37% across sites (Implementation), and 49% of patients remained in care at six months (Maintenance). Facilitators included training on SPC protocols, simplicity of dispensing the regimen, and perceived improvements in patient adherence. Challenges included SPC stockouts and concerns regarding nonphysician HCW capacity to manage complex cases. Policymakers identified the potential role of a Drug Revolving Fund (DRF) to support sustained SPC supply. The findings indicate favorable implementation outcomes associated with SPC use by nonphysician HCWs in PHCs. Addressing supply challenges, maintaining training, and providing supportive supervision may be important for sustaining SPC-based hypertension treatment.
- Open Access
- 17 January 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (1) , e0000549
Nigeria healthcare worker SARS-CoV-2 serology study: Results from a prospective, longitudinal cohort
Healthcare workers, both globally and in Nigeria, have an increased risk for SARS-CoV-2 infection compared with the general population due to higher risk contacts, including occupational exposures. In addition, primary healthcare workers represent an important group for estimating prior infection to SARS-CoV-2 because they work at the first point-of-contact for most patients yet have not been included in prior COVID-19 seroepidemiology research in Nigeria. We sought to evaluate baseline seroprevalence, rates of seroconversion (IgG- to IgG+) and seroreversion (IgG+ to IgG-), change in IgG concentration at 3- and 6-month follow-up, and factors associated with seropositivity. From June 2020 to December 2020, we conducted a longitudinal seroepidemiology study among frontline health care workers in Nigeria using a validated dried blood spot assay. Among 525 participants, mean (SD) age was 39.1 (9.7) years, 61.0% were female, and 45.1% were community health workers. The six-month follow-up rate was 93.5%. Seropositivity rates increased from 31% (95% CI: 27%, 35%) at baseline to 45% (95% CI: 40%, 49%) at 3-month follow-up, and 70% (95% CI: 66%, 74%) at 6-month follow-up. There was a corresponding increase in IgG levels from baseline (median = 0.18 ug/mL) to 3-month (median = 0.35 ug/mL) and 6-month follow-up (median = 0.59 ug/mL, Ptrend < .0001). A minority of participants reported symptoms from February 2020 until baseline (12.2%) or during 3-month (6.6%) or 6-month (7.5%) follow-up. only 1 participant was hospitalized. This study demonstrated high baseline, 3-month and 6-month follow-up prevalence of IgG antibodies to SARS-CoV-2 during the first two waves of the COVID-19 pandemic in Nigeria among a cohort of unvaccinated frontline healthcare workers, including primary healthcare workers despite low symptomatology. These results may have implications in state- and national-level disease pandemic modeling. Trial registration: NCT04158154.
- 17 January 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (1) , e0000549
Open AccessNigeria healthcare worker SARS-CoV-2 serology study: Results from a prospective, longitudinal cohort
Healthcare workers, both globally and in Nigeria, have an increased risk for SARS-CoV-2 infection compared with the general population due to higher risk contacts, including occupational exposures. In addition, primary healthcare workers represent an important group for estimating prior infection to SARS-CoV-2 because they work at the first point-of-contact for most patients yet have not been included in prior COVID-19 seroepidemiology research in Nigeria. We sought to evaluate baseline seroprevalence, rates of seroconversion (IgG- to IgG+) and seroreversion (IgG+ to IgG-), change in IgG concentration at 3- and 6-month follow-up, and factors associated with seropositivity. From June 2020 to December 2020, we conducted a longitudinal seroepidemiology study among frontline health care workers in Nigeria using a validated dried blood spot assay. Among 525 participants, mean (SD) age was 39.1 (9.7) years, 61.0% were female, and 45.1% were community health workers. The six-month follow-up rate was 93.5%. Seropositivity rates increased from 31% (95% CI: 27%, 35%) at baseline to 45% (95% CI: 40%, 49%) at 3-month follow-up, and 70% (95% CI: 66%, 74%) at 6-month follow-up. There was a corresponding increase in IgG levels from baseline (median = 0.18 ug/mL) to 3-month (median = 0.35 ug/mL) and 6-month follow-up (median = 0.59 ug/mL, Ptrend < .0001). A minority of participants reported symptoms from February 2020 until baseline (12.2%) or during 3-month (6.6%) or 6-month (7.5%) follow-up. only 1 participant was hospitalized. This study demonstrated high baseline, 3-month and 6-month follow-up prevalence of IgG antibodies to SARS-CoV-2 during the first two waves of the COVID-19 pandemic in Nigeria among a cohort of unvaccinated frontline healthcare workers, including primary healthcare workers despite low symptomatology. These results may have implications in state- and national-level disease pandemic modeling. Trial registration: NCT04158154.